Compare Citius Pharmaceuticals Inc (CTXR) vs BlackRock TCP Capital Corp (TCPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs BlackRock TCP Capital Corp — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while BlackRock TCP Capital Corp trades at $4.03 (market cap $337.71M). The key difference: BlackRock TCP Capital Corp is far larger — about 24.8× Citius Pharmaceuticals Inc's market cap, and BlackRock TCP Capital Corp pays a 18.88% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and BlackRock TCP Capital Corp for 88 Days on average.
| CTXR | TCPC | |
|---|---|---|
Market Cap | $13.62M | $337.71M |
Volume | 132,438 | 436,109 |
Sector | Health | Financials |
52-Week High | $1.82 | $6.20 |
52-Week Low | $0.48 | $3.13 |
Typical Hold Time | 17 Days | 88 Days |
Enterprise Value | $3.79M | $1.09B |
Dividend Yield | — | 18.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4994, down 1.73% with a bearish technical signal despite oscillators showing oversold conditions. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR commercial sales, but continues to post significant losses with a -651.27% net income margin. Recent news highlights strong commercial momentum for LYMPHIR with 44 institutions ordering the treatment since launch.
The stock presents a high-risk opportunity with analyst consensus strongly bullish (83% buy ratings, $5 price target) but fundamental challenges persist. Key risks include ongoing cash burn and execution of commercial strategy, while potential upside depends on successful LYMPHIR adoption and path to profitability.
TCPC trades at $4.01, up 1.78% with a bullish technical signal from moving averages. The company reported Q2 2026 EPS of $0.22, beating expectations, and announced a $523 million portfolio sale to reduce leverage. Despite negative revenue and net income trends, the stock trades at a discount to book value with a P/B of 0.61. Analyst consensus shows 30.77% buy ratings with no sell recommendations.
The outlook remains cautious due to declining revenue and negative profitability metrics, though strategic portfolio sales and dividend payments provide some stability. Key risks include ongoing net losses and class action litigation, while institutional sentiment appears mixed with technical indicators suggesting near-term bullish momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →
